Treatment with CRYSVITA® restores phosphate homeostasis in adults and children with XLH leading to clinically meaningful improvements¹⁻⁶

As of Sep 2020, CRYSVITA® has been approved by Korea MFDS (Ministry of Food and Drug Safety) for the treatment of FGF-23 related hypophosphatemic rickets and osteomalacia.7

Product is approved in EU/US/Japan and selected markets in Asia Pacific. Local approved prescribing information may differ. Please refer to local approval status and prescribing information before prescribing.

CRYSVITA® demonstrates rapid and significant improvements in biochemical and clinical outcomes in children with XLH1,3*

CRYSVITA® significantly improved rickets healing and reduced severity1,3

CRYSVITA® significantly improved growth and mobility outcomes1,3

CRYSVITA® significantly improved biochemical markers of phosphate regulation and bone health1,3

*Based on a Phase 2 and a Phase 3 study. In the Phase 2 study, 52 children with XLH aged 5–12 years were randomised to receive CRYSVITA® either every 2 weeks or every 4 weeks (dose was titrated according to serum phosphorus concentration). In the Phase 3 study, 61 children with XLH aged 1–12 years were randomised to receive either CRYSVITA® (0.8 mg/kg starting dose, administered every 2 weeks) or conventional therapy (oral phosphate and Vitamin D). In both studies, change in rickets was assessed at 40 weeks.

CRYSVITA® restores phosphate homeostasis in adults with XLH by targeting pathophysiology4,5

CRYSVITA® improves stiffness, functional disability and pain in adults with XLH4,5

CRYSVITA® is associated with greater healing of pseudofractures/fractures in adults with XLH6

CRYSVITA® is given as a subcutaneous injection every 4 weeks in adults7

CRYSVITA® treatment was well tolerated and had an acceptable safety profile in adults with XLH4,5

1. Carpenter TO, et al. N Engl J Med. 2018;378:1987–98. 2. Whyte MP, et al. Lancet Diabetes Endocrinol 2019;7:189–99. 3. Imel EA,et al. Lancet. 2019;393:2416–27. 4. Insogna KL, et al J Bone Miner Res. 2018;33:1383-9. 5. Portale AA, et al. Calcif Tissue Int. 2019;105:271-84. 6. Insogna KL, et al. J Bone Miner Res. 2019;34:2183-91. 7. CRYSVITA® (burosumab). Based on Korean Insert paper. Kyowa Kirin Korea Ltd;Sep 2020